Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria

July 1, 2026 02:13 PM EDT R&DPharma Mer­ck scraps a Phase 2 Alzheimer's as­set from part­ner Ne­upho­ria Kyle LaHucik Biotech Correspondent Mer­ck has axed a Phase 2 tri­al test­ing an ex­per­i­men­tal Alzheimer’s med­i­cine, End­points News has learned. The com­pa­ny ter­mi­nat­ed a mid-stage … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER